New peptide drug aims to tame sepsis in pneumonia patients

NCT ID NCT06669403

Not yet recruiting Disease control Sponsor: Op-T LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tests a drug called OPT101 in 26 adults hospitalized with pneumonia and sepsis. The drug is designed to reduce harmful inflammation. The main goal is to check safety and how the body processes the drug, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OPT101 (a peptide designed to reduce inflammation)
What this could lead to: If it works, this could point toward a new treatment to control dangerous inflammation in pneumonia patients with sepsis.
What could go wrong: This is a very early Phase 1 trial with only 26 people, focused on safety. It may not show any benefit, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMMUNITY-ACQUIRED PNEUMONIA (CAP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Community-Acquired Pneumonia infectious disease with sepsis pneumonia Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COMMUNITY-ACQUIRED PNEUMONIA (CAP) SEPSIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Denver Health and Hospital Authority

Denver, Colorado, 80204, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.